EPLERENONE

Search structure
Trade Names:
Synonyms:
Status: Approved (2002)
Entry Type: Small molecule
Molecule Category: Parent
ATC: C03DA04
UNII: 6995V82D0B

Structure
InChI Key JUKPWJGBANNWMW-VWBFHTRKSA-N
Smile COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13
InChI
InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H30O6
Molecular Weight 414.5
AlogP 3.12
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 1.0
Polar Surface Area 82.2
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 30.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Mineralocorticoid receptor antagonist DailyMed
Primary Target
Mineralocorticoid receptor
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 1
- 18000 - 3162 -
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 2
100 63-2600 - 126 44-111
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 3 Nuclear hormone receptor subfamily 3 group C Nuclear hormone receptor subfamily 3 group C member 3
- - - 19953 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Heart Failure 4 D006333 ClinicalTrials
Muscular Dystrophy, Duchenne 3 D020388 ClinicalTrials
Renal Insufficiency, Chronic 3 D051436 ClinicalTrials
Cardiomyopathies 3 D009202 ClinicalTrials
Essential Hypertension 3 D000075222 ClinicalTrials
Atrial Fibrillation 2 D001281 ClinicalTrials
Hyperparathyroidism, Primary 2 D049950 ClinicalTrials
Central Serous Chorioretinopathy 2 D056833 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Diabetic Nephropathies 2 D003928 ClinicalTrials
Diabetes Mellitus, Type 2 1 D003924 ClinicalTrials

Related Entries

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Endocrine disorders Diabetes mellitus 26.0
Renal and urinary disorders Proteinuria 26.0
Investigations Protein urine present 26.0
Endocrine disorders Diabetes mellitus 18.0
Renal and urinary disorders Proteinuria 18.0
Investigations Protein urine present 18.0
Endocrine disorders Diabetes mellitus 17.9
Renal and urinary disorders Proteinuria 17.9
Investigations Protein urine present 17.9
Endocrine disorders Diabetes mellitus
Endocrine disorders Diabetes mellitus 16.0
Renal and urinary disorders Proteinuria
Renal and urinary disorders Proteinuria 16.0
Investigations Protein urine present
Investigations Protein urine present 16.0
Endocrine disorders Diabetes mellitus 15.9
Renal and urinary disorders Proteinuria 15.9
Investigations Protein urine present 15.9
Endocrine disorders Diabetes mellitus
Renal and urinary disorders Proteinuria
Investigations Protein urine present
Endocrine disorders Diabetes mellitus
Renal and urinary disorders Proteinuria
Investigations Protein urine present
Endocrine disorders Diabetes mellitus
Renal and urinary disorders Proteinuria
Investigations Protein urine present
Cardiac disorders Dizziness 3.0
General disorders and administration site conditions Asthenia 2.0
Respiratory, thoracic and mediastinal disorders Cough 2.0
Gastrointestinal disorders Diarrhoea 2.0
Cardiac disorders Dizziness
General disorders and administration site conditions Fatigue 2.0
General disorders and administration site conditions Influenza like illness 2.0
Gastrointestinal disorders Abdominal pain 1.0
Renal and urinary disorders Albuminuria 1.0
General disorders and administration site conditions Asthenia
Investigations Blood triglycerides increased 1.0
Respiratory, thoracic and mediastinal disorders Cough
Gastrointestinal disorders Diarrhoea
General disorders and administration site conditions Fatigue
Gastrointestinal disorders Gastrointestinal pain 1.0
Metabolism and nutrition disorders Hypercholesterolaemia 1.0
Metabolism and nutrition disorders Hypertriglyceridaemia 1.0
General disorders and administration site conditions Influenza like illness

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
12.42
Cardiac disorders
11.6
Investigations
8.3
Vascular disorders
8.04
Nervous system disorders
7.88
Metabolism and nutrition disorders
7.55
Renal and urinary disorders
6.31
Gastrointestinal disorders
5.54
Respiratory, thoracic and mediastinal disorders
4.54
Injury, poisoning and procedural complications
4.53
Skin and subcutaneous tissue disorders
4.45
Musculoskeletal and connective tissue disorders
3.33
Infections and infestations
2.36
Psychiatric disorders
2.23

Cross References

Resources Reference
CAS NUMBER 107724-20-9
ChEBI 31547
ChEMBL CHEMBL1095097
DrugBank DB00700
DrugCentral 1032
EPA CompTox DTXSID2046094
FDA SRS 6995V82D0B
Human Metabolome Database HMDB0014838
Guide to Pharmacology 2876
KEGG C12512
PDB YNU
PubChem 443872
SureChEMBL SCHEMBL21515
ZINC ZINC000003985982
CONTENTS